skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration
Collaborations are commonplace in HIV treatment trials and leverage expertise and experience of individual parties as researchers work toward ending this ongoing epidemic, but does study implementation slow down when too many parties are involved? In particular, is there any impact on recruitment rates when various sponsor types collaborate?

Highlights in this white paper include:

This analysis takes a closer look at Phase II-III studies in HIV-positive patients in order to determine whether collaboration has any effect on enrollment trends in clinical trials evaluating antiretroviral treatment.
 
 

 

  • Average site and trial enrollment rates for single sponsor vs.
    collaborative studies by sponsor type
  • The effect of collaboration and number of sponsors on trial performance levels
  • How site enrollment rates and number of sites differ for four sponsor types,
    including industry, collaborative group, government agency and hospital/academic/medical center
  • The effect of trial size on enrollment trends and more


Dec-2014_Collaborations-in-HIV-treatment-trials_Doro-Shin

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: